EQ 10-Q filed 2026-11-12 | Key takeaways
EQ filed its 10-Q; the most relevant disclosure change is added Subsequent Events - Milestone Financing: On October 26, 2026, the company announced dosing of its first patient in a single ascending dose trial of EQ504 in Australia, constituting the Milestone Event. The company issued 14,957,260 shares of common stock and pre-funded warrants to purchase 20,130,457.
Read source-backed brief